Pharma Notes

APPOINTmENTS

LAB Research Inc. (LRI) announces the nomination of Mr. Yvan Landry as a new member of its board of directors and the resignation of Mr. Richard Lacombe who is stepping down to focus on other professional obligations. As part of the conditions of a Standby Purchase agreement signed at the time of a September 2009 Rights Offering, LRI granted Solidarity Fund QFL the right to nominate two individuals on LRI’s board of directors, including one who may be an employee of the FSTQ. Mr. Landry is a certified management accountant who has spent most of his 25-year career with Solidarity Fund QFL, including the last five years as part of the Fund’s Health Care Group.

Jeff O’Hagan has been named chief executive officer of Sunnybrook Foundation, effective April 1, 2010. O’Hagan is currently the Foundation’s senior vice president of development. In addition to managing all operations, O’Hagan will lead the Foundation to achieve the goals of the $470-million Campaign for Sunnybrook, publicly launched in November. Before joining Sunnybrook in 2007, O’Hagan held senior fundraising roles at University of Western Ontario and St. Mary’s General Hospital Foundation in Waterloo. Prior to his entrée into the fundraising sector, O’Hagan enjoyed a successful career in wealth management and estate services at RBC.

Canadian oncology CRO Scimega Research has appointed Dr. Luc Daigneault to the position of director Scientific Affairs. Dr. Daigneault completed his PhD in Molecular Biology at the Cancer Institute of Montreal, Notre-Dame Hospital, in 1991. Over the course of his career, Dr. Daigneault has held several strategic positions of increasing responsibility within the biopharmaceutical industry and was involved in the clinical development of several products in oncology and other indications such as HIV and neuropathic pain.

Baljit S. Chadha has joined the board of directors of Warnex. Baljit Singh Chadha, PC, has significant expertise in international trade, marketing and strategic planning. He is president of Balcorp Limited, an international trade and marketing firm, which he founded in 1976 and built into a successful company with about $100 million in sales and offices in Montreal, New Delhi and Mumbai. Balcorp has diversified interests in agri-food products, forestry products, minerals and services. He is also a well known philanthropist and a leader of the Indian community in Canada. He has been a key player in a number of international trade missions and treaty development processes. He also sits on the Board of Governors of Concordia University, has advised the Office of the Mayor of Montreal on Indo-Canadian affairs and has served on the advisory board of the Indo-Canada Chamber of Commerce. In 2003, he was appointed by Prime Minister Jean Chretien to the Security Intelligence Review Committee as well as the Queen’s Privy Council for Canada.

B. Mario Pinto, one of Canada’s leading chemical biologists, has joined Sirona Biochem Corp. scientific advisory board. Professor Pinto is a pioneer in the field of chemical biology having developed novel NMR/molecular modeling protocols for protein structure determination and the study of ligand topographies essential for drug and vaccine design. His work also involves the synthesis of antiviral and antibacterial drugs, bacterial vaccines, and new methods of viral control. He has authored 168 scientific papers, 147 other publications which include books and technical reports, and has numerous memberships and awards, including the 1992 Horace S. Isbell Award from the Carbohydrate Division of the American Chemical Society of which he is a member, the 1993 Merck Frosst Award of the Canadian Society for Chemistry (CSC), the 2002 Bernard Belleau Award of the CSC, and the 2005 British Columbia Innovation Council Frontiers in Research Award. He is also a member of the Royal Society of Canada and is Chair of its Selection Committee for the Rutherford Memorial in Chemistry Medal. He has served as the president of the International Carbohydrate Organization, and serves as the vice-president of the Canadian Society for Chemistry.

PharmaNet Development

Group, Inc. announces that Stephen Kasay has joined the company as chief information officer. In his role, Kasay will have global responsibility for the company’s corporate information technology function including strategy development and execution and optimization of the company’s technology infrastructure, software and data assets. Mr. Kasay has over twenty years of experience providing direction to information technology (IT) departments in global pharmaceutical companies and clinical research organizations. His accomplishments include the strategic assessment and consolidation of data, the successful implementation of software and infrastructure assets to enhance productivity, the establishment of global IT governance processes, and the development of relationships and communication practices with business partners to continually improve efficiencies and client service.

Afexa Life Sciences Inc. announces the appointment of Jack Moffatt as chairman and chief executive officer of the company, effective immediately. In mid-2007, Mr. Moffatt became an advisor to management and the board of directors of the company. In September 2008 he was appointed to the Board and became its executive chair. The following month he assumed oversight responsibility for the company’s day-to-day operations. With an extensive background in packaged-goods retailing and manufacturing in Canada and the US, Mr. Moffatt has held senior management positions in several industries. He is a former chairman and chief executive officer of The Great Atlantic and Pacific Tea Company, and a past president, Control Brands Division, The Cott Corporation. He also served as president of First National Supermarkets, Ltd. Mr. Moffatt holds an MBA degree from the University of Toronto.

Sirius Genomics, a developer of pharmacogenomic diagnostics, announces that Chris Wagner has been appointed president and chief executive officer, replacing Dr. Brad Popovich. Dr. Popovich will continue as member of Sirius Genomics board and will continue to assist Mr. Wagner and the company with the provision of strategic advice and support. Mr. Wagner has over 17 years of experience in marketing, sales and business development. Since 2007, Mr. Wagner was vice president of Business Development at Sirius Genomics. Previously, he was with Aspreva Pharmaceuticals as the vice president of Marketing and vice president of Business Development. Prior to Aspreva, Mr. Wagner was with Eli Lilly as an international service employee working in Europe, North America and Asia with positions based in Toronto, Indianapolis and Boston. Mr. Wagner holds a BSc in Organic Chemistry from the University of British Columbia.

SIZE REDUCTION AND HOMOGENIZATION OF FOODSTUFFS

KNIFE MILL GRINDOMIX GM 300

Fast and reproducible homogenization of food samples with a high water, fat or oil content

Homogenization of volumes up to 4,500 ml Autoclaveable grinding tools Powerful 1.1 kW industrial motor www.retsch-us.com/gm300

PADDLE BLENDER PB 100

Efficient sample preparation for subsequent microbiological food testing

With patented SMASH effect Very quiet operation, short blending time (30 sec – 1 min) No blockage due to automatic overload protection www.retsch-us.com/pb100 www.retsch-us.com/pb100

Ask for our special introductory offers!

www.retsch-us.com/superheroes

74 Walker Lane · Newtown, PA 18940 1-866-4-RETSCH · info@retsch-us.com

Reply card #4297